Correlation between the presence of neutralizing antibodies against porcine circovirus 2 (PCV2) and protection against replication of the virus and development of PCV2-associated disease.
about
Immunity Elicited by an Experimental Vaccine Based on Recombinant Flagellin-Porcine Circovirus Type 2 Cap Fusion Protein in PigletsModelling the time-dependent transmission rate for porcine circovirus type 2 (PCV2) in pigs using data from serial transmission experiments.Cellular adaptive immune response against porcine circovirus type 2 in subclinically infected pigsDynamics of serum antibodies to and load of porcine circovirus type 2 (PCV2) in pigs in three finishing herds, affected or not by postweaning multisystemic wasting syndromeThe comparative profile of lymphoid cells and the T and B cell spectratype of germ-free piglets infected with viruses SIV, PRRSV or PCV2.Reduction of porcine circovirus type 2 (PCV2) viremia by a reformulated inactivated chimeric PCV1-2 vaccine-induced humoral and cellular immunity after experimental PCV2 challenge.Antibody recognition of porcine circovirus type 2 capsid protein epitopes after vaccination, infection, and disease.Co-expression of ubiquitin gene and capsid protein gene enhances the potency of DNA immunization of PCV2 in micePCV2 vaccination induces IFN-γ/TNF-α co-producing T cells with a potential role in protection.T-cell reprogramming through targeted CD4-coreceptor and T-cell receptor expression on maturing thymocytes by latent Circoviridae family member porcine circovirus type 2 cell infections in the thymus.Assessing PCV2 antibodies in field pigs vaccinated with different porcine circovirus 2 vaccines using two commercial ELISA systemsVariation in time and magnitude of immune response and viremia in experimental challenges with Porcine circovirus 2b.Comparative efficacy of experimental inactivated and live-attenuated chimeric porcine circovirus (PCV) 1-2b vaccines derived from PCV1 and PCV2b isolates originated in China.Impact of maternally derived immunity on piglets' immune response and protection against porcine circovirus type 2 (PCV2) after vaccination against PCV2 at different ageRNA-Seq Analysis Reveals Genes Underlying Different Disease Responses to Porcine Circovirus Type 2 in Pigs.A randomized controlled study on the efficacy of a novel combination vaccine against enzootic pneumonia (Mycoplasma hyopneumoniae) and porcine Circovirus type 2 (PCV2) in the presence of strong maternally derived PCV2 immunity in pigs.Effect of sow vaccination against porcine circovirus type 2 (PCV2) on virological profiles in herds with or without PCV2 systemic diseaseThe index herd with PMWS in Sweden: presence of serum amyloid A, circovirus 2 viral load and antibody levels in healthy and PMWS-affected pigs.Evaluation of natural porcine circovirus type 2 (PCV2) subclinical infection and seroconversion dynamics in piglets vaccinated at different ages.Effect of porcine circovirus type 2 (PCV2) vaccination on PCV2-viremic piglets after experimental PCV2 challenge.Best practice and future challenges for vaccination against porcine circovirus type 2.Time course differential gene expression in response to porcine circovirus type 2 subclinical infection.Pigs naturally exposed to porcine circovirus type 2 (PCV2) generate antibody responses capable to neutralise PCV2 isolates of different genotypes and geographic origins.Inhibition of endosome-lysosome system acidification enhances porcine circovirus 2 infection of porcine epithelial cells.Inactivated chimeric porcine circovirus (PCV) 1-2 vaccines based on genotypes 2b and 2d exhibit similar immunological effectiveness in protecting pigs against challenge with PCV2b strain 0233.Exploitation of stable nanostructures based on the mouse polyomavirus for development of a recombinant vaccine against porcine circovirus 2.Efficacy of single dose of an inactivated porcine circovirus type 2 (PCV2) whole-virus vaccine with oil adjuvant in piglets.Unusual outcome of in utero infection and subsequent postnatal super-infection with different PCV2b strains.Protective immunity conferred by porcine circovirus 2 ORF2-based DNA vaccine in mice.Genomic analysis of the differential response to experimental infection with porcine circovirus 2b.Porcine circovirus type 2 (PCV2)-infection and re-inoculation with homologous or heterologous strains: virological, serological, pathological and clinical effects in growing pigs.Experimental co-infection of pigs with Bovine viral diarrhea virus 1 and Porcine circovirus-2.Development of porcine circovirus 2 (PCV2) open reading frame 2 DNA vaccine with different adjuvants and comparison with commercial PCV2 subunit vaccine in an experimental challenge.Porcine circovirus 2 immunology and viral evolution.
P2860
Q27326717-7952324D-7954-4C30-832E-81EB10F3153BQ31159468-D32CC665-2FC5-42BD-8584-0ABE0A51B9FCQ33520377-D52183A5-A70A-42B7-AC32-BE9A0111C751Q33780340-79D78883-01E6-44E8-B134-E019745A4F7DQ34145808-F36B9FB2-19CF-4A9B-99AD-9A3F2BEF69C2Q34451426-DBBC3DC6-DC1B-4394-BE79-0E760137840FQ35066205-35EA67BF-270B-4315-8E19-25C38D44B43AQ35102883-CC4C719A-CC0F-4FEB-9846-3B06A3BAAE4CQ35142582-E556A82A-4DB0-43EB-ACA6-C20CE2447C86Q35164842-0ED9825C-FDDA-440D-8713-63D5745E5571Q35199079-F7FD9FC2-685D-4177-AC12-8A7DAC87EEB1Q35487036-F1263565-FBAE-4D28-8C7F-C7E2CDA96899Q35899051-2BFE84F6-905C-4855-87F4-4CB382E35839Q36015138-DFB9161C-395B-4164-B70D-29D722F18B50Q36015404-62F5C0E4-0527-4792-AEA8-BE5304564FCAQ36340432-6CFF5414-4849-4FF9-9741-53E58FAC6D67Q36900388-4F54CF63-AF1C-47C8-B77D-7D42C27BD2B2Q37185952-D3E48468-603A-48AA-A16A-194B07F5FC9AQ37470430-0EB91712-3E93-4B46-973D-8D87F5561104Q37581980-26A8A1B8-0B51-4AA4-995A-7C49DE06D003Q38268599-3587B825-F3E3-42F1-8314-DD10CAE7EB43Q38508707-A37251AE-3A7D-4315-844A-4D508632C100Q38903870-F4C68E8D-3757-4AC7-911D-FBABB6CA94D6Q40046355-E176FA85-9377-49D7-A5E0-B3D77780137CQ40512056-9824B4BC-0640-4A7E-8790-F7F5EAEBD0AEQ41702578-81DD8D7E-5B50-496D-B76C-D3AF8A551E7FQ42007715-FC5A2945-2218-4623-A216-C9E83BF8083BQ42211002-98FEE0F2-0ACC-4E9B-A17C-7C54C1D3CA77Q42214536-E01B0022-49D0-408A-B3FE-5A6A0E68501CQ42242311-1C6BF8CC-C438-4D20-AD1B-148B1181A6F3Q42910025-57A29E80-3E17-454D-A4AE-C8CB6FF5BD16Q42977970-C0716FA8-0C4C-470C-8C24-4BDBEBFA4B19Q47102234-C82E691F-B083-449E-A632-C1CCE1BB18EAQ50938133-273A4A99-EA98-4E73-B04F-F2031BCC5B4F
P2860
Correlation between the presence of neutralizing antibodies against porcine circovirus 2 (PCV2) and protection against replication of the virus and development of PCV2-associated disease.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Correlation between the presen ...... ent of PCV2-associated disease
@nl
Correlation between the presen ...... nt of PCV2-associated disease.
@ast
Correlation between the presen ...... nt of PCV2-associated disease.
@en
type
label
Correlation between the presen ...... ent of PCV2-associated disease
@nl
Correlation between the presen ...... nt of PCV2-associated disease.
@ast
Correlation between the presen ...... nt of PCV2-associated disease.
@en
prefLabel
Correlation between the presen ...... ent of PCV2-associated disease
@nl
Correlation between the presen ...... nt of PCV2-associated disease.
@ast
Correlation between the presen ...... nt of PCV2-associated disease.
@en
P2093
P2860
P3181
P356
P1476
Correlation between the presen ...... nt of PCV2-associated disease.
@en
P2093
Charlotte S Kristensen
David Lefebvre
Gerald Misinzo
Jens Nielsen
Peter Meerts
P2860
P2888
P3181
P356
10.1186/1746-6148-2-6
P407
P577
2006-01-30T00:00:00Z
P5875
P6179
1040782969